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Abstract 
In 2014 we introduced anti-thymocyte globulin (ATG) to the graft-versus-host disease (GvHD) prophylaxis 
regimen in allogeneic stem cell transplantation (Allo-HSCT) with peripheral stem cells (PBSC) from matched 
unrelated donors (MUD). We analysed the outcomes of 415 patients who went through MUD allo-HSCT and 
received PBSC with or without ATG. We report dramatic reduction of the incidence of chronic GvHD and our 
study illustrates the benefit of ATG in addition to standard GvHD prophylaxis. 
Anti-thymocyte globulin (ATG) is commonly used to prevent graft-versus-host disease (GvHD) after allogeneic 
hematopoietic stem cell transplantation (allo-HSCT). To evaluate the impact of ATG as part of the GvHD prophylaxis in 
our institution, we report the outcome of 415 patients with matched unrelated donors (MUD) transplanted for hemato- 
logical malignancies with or without ATG from 2005 to 2019 at Oslo University Hospital, Norway. The following groups 
were compared: (1) 154 patients transplanted with peripheral blood stem cells (PBSC) without ATG 2005-2014. (2) 137 
patients transplanted with bone marrow stem cells (BMSC) 2005-2019. (3) 124 patients transplanted with PBSC and 
ATG (PBSC + ATG) 2014-2019. Three years survival was similar in the groups, 61% following allografting with PBSC, 
54% with BMSC, and 59% with PBSC + ATG. Acute GvHD grade III-IV was 14%, 14%, and 7%; chronic GvHD was 81%, 
32, and 26%; and extensive cGvHD 44%, 15%, and 6% in the corresponding groups. Both acute and chronic GvHD were 
significantly reduced in the PBSC + ATG-versus the PBSC group (p < 0.05 and p < 0.001 respectively).Transplant- 
related mortality (TRM) was 33%, 25%, and 17% (p = 0.18). Graft versus host disease and relapse free survival (GRFS) 
at 3 years was 43 %, 43%, and 64% in the groups. Adding ATG to the GvHD prophylaxis regimen of MUD allo-HSCT with 
PBSC resulted in a substantial reduction of both acute and chronic GvHD without compromising the disease control, 
reflected in a superior 3 years GRFS. 
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Allo-HSCT has the potential to cure hematological malignan-
cies. However, it is associated with severe morbidity and mortality. 1,2 
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//doi org/10 1016/j clml 2021 05 003cles for cure and maintaining good quality of life after transplan-
tation. 3-5 Individual thorough risk assessment before proceeding to
transplant is required. An HLA-matched related donor (MRD) is
still considered the best donor choice, although outcomes following
transplants with matched unrelated donor (MUD) are approaching
those of MRDs. 6-9 
The most frequently available source of allogeneic stem cells is
currently PBSC from a MUD. Both PBSC compared to BMSC and
MUD compared to MRD are associated with increased frequency
and severity of GvHD. 10-12 Early studies suggested that adding
ATG to GvHD prophylaxis was associated with delayed immune
reconstitution and increased risk of viral infections, particularly
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivation
in addition to an increased risk of relapse. 10 However, addition of
ATG to GvHD prophylaxis has been shown in several randomizedClinical Lymphoma, Myeloma and Leukemia 2021 1 
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2 Cliprospective trials to significantly reduce cGvHD and to improve
GvHD and relapse free survival (GRFS). 11-16 In the only double-
blind trial in MUD/MAC, allo-HSCT ATG lowered moderate
to severe cGvHD, but progression free survival (PFS) and overall
survival (OS) also were lower, indicating that additional analy-
ses are needed to understand the appropriate role for ATG in
allo-HSCT. 19 
There is also evidence that addition of ATG may reduce cGvHD
in the MRD setting. 14,17 
The standard backbone regimen to prevent GvHD is the combi-
nation of a calcineurin inhibitor and methotrexate. 18 Ex-vivo T-
cell depletion, monoclonal antibodies, and in vivo T-cell depletion
or post-transplant cyclophosphamide are supplementary alternatives
19-21 . 
The use of ATG has increased tremendously in the different trans-
plant modalities 10,22-24 and is now part of the GvHD prophylaxis
in most European transplant centers, both for PBSC- as well as
BMSC/MUD transplants. 
ATG products differ in their manufacturing process, including
the cell line used for immunization as well as the animals used for
production. Anti-thymoglobulin is a polyclonal IgG immunoglob-
ulin generated in rabbits by immunizing with either human thymo-
cytes (Thymoglobulin: Sanofi, Paris, France) or with the Jurkat
T-lymphoblastoid cell line (ATG-Fresenius, rebranded now as
Grafalon, Neovii Biotech, GMBH, Gr ӓfelfing, Germany). ATG
binds directly to T-cell surface epitopes and induces complement-
dependent cell lysis, thereby suppressing the recipients T-cell
function. Due to its long half-life, ATG also interacts with the trans-
planted donor T-cells and evolving immune cells during engraft-
ment. Its suppressive action on donor T-cells is the rationale for
use as GvHD prophylaxis. ATG delays post-transplant lymphocyte
recovery and increases the risk for infections, especially viral infec-
tions. 25,26 
In reduced intensity conditioning (RIC), the curative potential of
the allo-HSCT is largely dependent on the donor T-cell graft-versus-
leukemia (GVL) effect. Soiffer et al have shown an increased risk of
relapse in RIC allo-HSCT with ATG, although in their study they
used both horse ATG and high doses of rabbit ATG (7 mg/kg). 22
Both Baron et al and Devillier et al showed that low doses ( <
6 mg/kg) of rabbit ATG (Thymoglobulin) are effective as GvHD
prophylaxis without compromising disease control and outcomes in
RIC. 23,24 
Several reviews and meta-analysis have confirmed the benefit of
ATG in preventing GvHD. 27-29 However, the trials are very hetero-
geneous regarding conditioning regimens, patient characteristics,
donor type, graft source, ATG brand, dosage, and timing of ATG
administration, making interpretation and comparison challeng-
ing. 30 
In 2014 we added ATG to the GvHD prophylaxis regimen
for patients undergoing allo-HSCT with PBSC from MUD in
our institution. We have performed a retrospective analysis of the
outcome in 415 patients who went through 10/10 MUD allo-
HSCT with or without ATG for hematological malignancies at
Oslo University Hospital. The aim of this retrospective analysis was
to evaluate the results of adding ATG to the GvHD prophylaxis
regimen in the MUD with PBSC. nical Lymphoma, Myeloma and Leukemia 2021 
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Patients 
We retrospectively collected data from 415 adult patients trans-
planted with 10/10 MUD for hematological malignancies ( Table 1 )
between 2005 and 2019 at Oslo University Hospital, Norway. 
The patients were categorized in three groups: (1) The PBSC
group: 154 patients who received PBSC with no ATG between 2005
and 2014 prior to implementation of ATG as part of the GvHD
prophylaxis. (2) The BMSC group: 137 patients receiving BMSC
without ATG between 2005 and 2019. (3) The PBSC + ATG
group: 124 patients receiving PBSC with ATG prophylaxis between
2014 and 2019. The patient characteristics are given in Table 1 . 
Conditioning and Stem Cell Source 
Myeloablative conditioning (MAC, n = 233) consisted of busul-
fan 16 mg/kg in combination with cyclophosphamide 120 mg/kg,
or fludarabin 150 mg/m ², or TBI 13 Gy and cyclophosphamide 120
mg/kg. Reduced intensity conditioning (RIC, n = 182) consisted
of fludarabin 150 mg/m ² in combination with treosulfan 42 g/m ²,
busulfan 8 mg/kg or cyclophosphamide 600 mg/m ², or TBI 2 Gy.
Eight patients received other MAC and RIC protocols. Prior to the
introduction of ATG, we strived to use BMSC in MAC transplants
because of the documented lower occurrence of cGvHD. Since the
curative potential of RIC allo-HSCT is largely dependent on the
donor T-cell graft-versus-leukemia (GVL) effect 31 , we routinely use
PBSC in the RIC setting. 
Donors 
For both donors and recipients, we performed high-resolution
HLA matching for the HLA-A, -B, -C, -DRB1, and -DQB1
gene loci on two different time points for each recipient-donor
pair. At least one typing was done in our hospital’s HLA labora-
tory accredited by the European Federation of Immunogenetics.
The other typing was performed either in our HLA laboratory or
in a donor registry contract HLA laboratory. Due to changes in
typing methods and technology from 2005 to 2018, combinations
of various genotyping techniques (eg, sequence-specific oligonu-
cleotide typing, sequence-specific primer typing, and sequence-
based typing) were used to achieve high-resolution typing results. 
GVHD Prophylaxis 
GvHD prophylaxis consisted of cyclosporine (CsA) in combi-
nation with methotrexate (MTX) on day + 1, + 3, + 6 (and + 11)
(n = 339), mycophenolate mofetil day 0 to + 28 (n = 9), or
sirolimus day -1 to + 2 (n = 60). Seven patients received CsA alone.
We administered a low dose ATG (Thymoglobulin) of 2
mg/kg/day in 2 days (total dose 4 mg/kg) for PBSC 10/10 MUD. 
Infection Prophylaxis 
All patients received antifungal and herpes virus prophylaxis
according to the European Conference on Infections in Leukemia
(ECIL) guidelines in force at that time. 32 Patients at risk for EBV-
or CMV reactivation were screened for viral replication according to
institutional guidelines. Preemptive treatment was initiated accord-
ing to the definitions given below. lin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells 
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Table 1 Patient and Transplant Characteristics 
PBSC PBSC + ATG BMSC p-value 
n 154 124 137 
Age (median, Q1-Q3) 53 (42-60) 61 (51-65) 42 (29-51) < 0.001 
Sex (M/F) 92/62 87/37 84/53 0.17 
Diagnosis: < 0.001 
AML/ALL 74 44 107 
CML 8 2 11 
Lymphoma/CLL 46 21 5 
MDS/MPN 25 56 14 
Stage: 0.02 
CR1/CP1 41 42 75 
CR2-3/CP2-3 41 26 38 
Later 9 6 5 
Unknown 63 50 19 
Donor age: 30 (24-38) 25 (22-33) 29 (22-36) < 0.001 
Sex mismatch: 
FtoM 25 (16%) 19 (15%) 22 (16%) 0.98 
CD34 dose (median, Q1-Q3) 6.7 (5.2-8.4) 6.9 (5.7-8.7) – 0.50 
TNC (median, Q1-Q3) – – 2.7 (2.1-3.4) 
Conditioning: 
MAC/RIC 92/62 11/113 130/7 < 0.001 
TBI-based 3 (2%) 5 (4%) 17 (12%) < 0.001 
GVHD prophylaxis: < 0.001 
CsA + MTX 106 100 133 
CsA + MMF 4 4 1 
CsA + Sirolimus 39 20 1 
CsA alone 5 0 2 
CMV sero-status pre SCT: 
Match/Mismatch 90/59 76/46 82/48 0.89 
M indicates male; F female; AML acute myeloid leukemia; ALL acute lymphoblastic leukemia; CLL chronic lymphocytic leukemia; MDS myelodysplastic syndrome; MPN myeloproliferative neoplasia; CR 
complete remission; CP chronic phase; FtoM female to male; SC stem cell; BMSC bone marrow stem cell; PBSC peripheral blood stem cell; TNC total nucleated cells; MAC myeloablative conditioning; 




































Engraftment was defined as absolute neutrophil count of at least
0.5 × 10 9 /L for 3 days and platelet count at least 20 × 10 9 /L
for 5 days without transfusions. CMV reactivation was defined as
quantitative value of CMV-DNA above 200 IU/ml and preemp-
tive treatment with ganciclovir alternatively foscavir are standard of
care. EBV reactivation was defined as quantitative value of EBV-
DNA above 1000 IU/ml. According to our institutional guidelines,
the threshold for EBV disease and preemptive EBV treatment with
Rituximab 375 mg/m b weekly up to 4 consecutive weeks was EBV
DNA levels ≥ 20 000 IU/ml. 
The procedures were performed in accordance with the Helsinki
declaration, and the study was approved by The Regional Commit-
tee for Medical and Health Research Ethics South East Norway and
the Data Protection Officer, Oslo University Hospital. 
Statistics 
The primary objective of the study was to analyze OS, GvHD,
GRFS, RFS, TRM, infections, CMV, and EBV reactivations in the
3 patient cohorts. Please cite this article as: M.M. Ali et al, Addition of Anti-thymocyte Globu
From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Re
//doi org/10 1016/j clml 2021 05 003The analysis was performed on September 19, 2019. OS,
RFS, and GRFS were calculated using the Kaplan-Meier method
and compared with the log-rank test. For GRFS, relapse, death,
severe acute GvHD (grades III-IV), and extensive chronic GvHD,
whichever came first, were considered the events. Transplant-
related mortality (TRM), GvHD, and relapse incidence (RI) were
estimated using a nonparametric estimator of cumulative incidence
curves taking competing events into consideration. Corrected multi-
variate risk factor analyses for TRM, RI, and GvHD were performed
using the proportional subdistribution hazard regression model
developed by Fine and Gray. Multivariate modeling for OS and
RFS was carried out using Cox regression models (to estimate hazard
ratios (HRs)). Corrections were made for the pretransplant factors
that were different between the three groups (patient and donor age,
diagnose, disease stage, RIC/MAC and GvHD prophylaxis). As the
study covered a long period (2005 through 2019), we also included
“year of HSCT” to correct for changes treatment performed during
this time frame. All p-values were two-tailed. Categorical parameters
were compared using the Chi-square test and continuous variables
were compared using the Mann-Whitney test or the Kruskal-WallisClinical Lymphoma, Myeloma and Leukemia 2021 3 
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Table 2 Causes of Death 
CoD BMSC PBSC PBSC + ATG 
Relapse 31 (23%) 16 (10%) 16 (13%) 
Infection 8 (6%) 19 (12%) 4 (3%) 
GVHD 4 (3%) 18 (12%) 6 (5%) 
MOF 14 (10%) 11 (7%) 6 (5%) 
Other 8 (6%) 12 (8%) 3 (3%) 































4 Clitest. Analysis was performed using Statistica 13 software (StatSoft,
Tulsa, OK) and the EZR statistical software. 
Results 
There was no significant difference in disease stage at trans-
plantation, gender mismatch, stem cell dose, or CMV serologi-
cal status pretransplant between the three groups. Patients in the
PBSC + ATG group were significantly older, received grafts from
younger donors, had the highest proportion of myelodysplastic
syndrome, and a significantly higher number received RIC. The
patient characteristics are given in Table 1 . 
Neutrophil Engraftment and Graft Failure 
The median time to neutrophil engraftment was 13 days for
the patients who received PBSC without ATG, interquartile range
(IQR) 9 days to 18 days. Five patients in this group died before
engraftment, and 1 experienced primary graft failure. 
For patients who received BMSC, the median time to neutrophil
engraftment was 21 days, IQR 18 days to 25 days. Three patients
in this group died before engraftment, and 2 suffered primary
graft failure. The median time to neutrophil engraftment for the
PBSC + ATG patients was 15 days, IQR 14 days to 18 days.
One patient in this group died before engraftment, and 2 had
primary graft failure. Time to neutrophil engraftment was signifi-
cantly longer in the BMSC group compared to both the PBSC (p
< 0.001) and the PBSC + ATG group (p < 0.001). ATG delayed
engraftment in patients receiving PBSC (p = 0.01). 
Infections 
Invasive fungal infections (IFI) were observed in 12% of patients
in the PBSC group compared to 19% and 14% in the BMSC and
PBSC + ATG groups (p = 0.26). CMV reactivation occurred in
44%, 32%, and 42% in the three groups, respectively (p = 0.08).
The cumulative incidence of EBV reactivation was 71% following
PBSC + ATG, which was significantly higher compared with the
BMSC and PBSC at 9% and 11%, respectively (p < 0.001). In spite
of the high EBV reactivation rate in the PBSC + ATG group, only
4 patients received rituximab for EBV reactivation preemptively
whereas 2 patients received rituximab for post-transplant lympho-
proliferative disease (PTLD). In one case, PTLD was diagnosed
postmortem. For a number of patients in the non-ATG group
(approximately 50%) and only 9% of the PBSC + ATG group,
EBV-PCR was not measured due to institutional standard of care
prior to implementation of ATG. 
Acute and Chronic GvHD 
The cumulative incidence of aGvHD grades II-IV in the PBSC
group was 42%, 41% in the BMSC group, and 27% in the
PBSC + ATG group (p = 0.007) ( Figure 1 A). 
The cumulative incidence of severe acute GvHD grades III-IV
in the PBSC, BMSC, and PBSC + ATG group were 14%, 14%,
and 7%, respectively ( Figure 1 B). The PBSC + ATG group had
significantly less severe aGvHD compared both to the BMSC group
(p < 0.05) and PBSC group (p = 0.045). 
The cumulative incidence of cGvHD was significantly higher in
the PBSC group (81%) compared to the BMSC group (32%, p <nical Lymphoma, Myeloma and Leukemia 2021 
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The incidence of extensive cGvHD was also significantly higher in
the PBSC group (44%) compared to the other two groups (15%
and 6%, respectively, p = 0.03). 
Treatment Related Mortality (TRM) 
There was no difference between the PBSC + ATG group and the
BMSC group regarding 3-year treatment-related mortality (17% vs
25%, p = 0.18). On the contrary, the 3-year TRM was significantly
lower in the PBSC + ATG group than in the PBSC group, 17%
and 33% respectively (p = 0.024) ( Figure 2 A). The TRM > 3 years
in the PBSC group is caused by infections (n = 5), secondary malig-
nancies (n = 3), suicide (n = 1), and “other” (n = 3). Among these
12 late TRM, 10 suffered from extensive cGvHD, which predispose
to the before-mentioned causes of death. 
GvHD and Relapse-free Survival (GRFS) 
Three years after transplantation, the rate of GRFS was 43%
for both the PBSC group and the BMSC group but 64% in the
PBSC + ATG group, p = 0.005. The addition of ATG to PBSC
increased GRFS significantly ( Figure 2 B). 
Relapse 
The cumulative incidence of relapse 3 years after transplanta-
tion was 11% in the PBSC, 24% in the BMSC, and 19% in the
PBSC + ATG group ( Figure 2 C). The relapse difference between
PBSC and BMSC was significant only in univariant analysis (p
< 0.01), and there was no relapse difference in PBSC + ATG vs
BMSC (p = 0.14) ( Figure 2 C). 
Survival 
Three years after transplantation, the probability of survival was
61% in the PBSC group, 54% in the BMSC group, and 59% in the
PBSC + ATG group ( Figure 2 D). There was no significant differ-
ence either in RFS or OS in the PBSC + ATG group compared
to the two other groups. Causes of death are presented in Table 2 .
The main causes of death both in the BMSC and the PBSC + ATG
groups are relapses. There is, however, no difference in relapse rates
in the PBSC and the PBSC + ATG groups ( Table 2 ). 
Multivariate Analysis 
In the corrected multivariate analysis, we found that the addition
of ATG to PBSC resulted in less chronic GvHD compared to
PBSC without ATG ( Table 3 ). GRFS was significantly better in
the PBSC + ATG group compared to the BMSC ( Table 3 ). Therelin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells 
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Figure 1 Cumulative incidence of (A) acute GvHD II-IV, (B) acute GvHD III-IV, and (C) chronic GvHD after MUD HSCT in patients 







































was a trend for less acute GvHD II-IV and better GRFS in the
PBSC + ATG group compared to the PBSC group. Chronic
GvHD tended to be higher in the BMSC group compared to the
PBSC + ATG group. 
Discussion 
GvHD and relapse are the major obstacles encountered after
allo-HSCT. The standard regimen for prevention of GvHD is the
combination of a calcineurin inhibitor and methotrexate. Due to an
unacceptable high incidence of cGvHD in patients transplanted up
to 2014 with PBSC from MUD in our institution, we implemented
ATG as part of the GvHD prophylaxis regimen in the MUD PBSC
setting from February 2014. 
The incidence of cGvHD was dramatically reduced from 81%
to 26% in patients receiving MUD PBSC after the introduc-
tion of ATG in the GvHD prophylaxis regimen without increas-
ing the incidence of relapse or leading to more graft failure. This
is in harmony with published data. 12,14,23,25,33,34 In fact, in our
material there is a trend toward lower incidence of cGvHD in
the PBSC + ATG group compared with the BMSC group. The
incidence of acute GvHD was also significantly reduced by adding
ATG. This is also in accordance with previous studies 29,35-37 ; as aPlease cite this article as: M.M. Ali et al, Addition of Anti-thymocyte Globu
From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Re
//doi org/10 1016/j clml 2021 05 003matter of fact, the incidence of severe aGvHD in the PBSC + ATG
group is lower than in the BMSC group. We raise the question as to
the outcome when ATG is added to the GvHD prophylaxis regimen
in patients allografted with BMSC. The available studies show
conflicting results. Bacigalupo et al showed significant reduction in
both severe aGvHD and cGvHD among MUD BMSC patients
who received ATG 7.5-10 mg/kg. 11 On the other hand, Ravinet
et al reported no significant impact of ATG in MUD BMSC. In
this study, various total doses of ATG were used at the discretion of
the attending physician (range < 5 to ≥10 mg/kg, only 10 patients
received ATG less than 5 mg/kg). 38 In both studies, Thymoglobulin
was used, as in our study. 
In the multivariate analysis corrected for patient and donor age,
diagnosis, disease stage, conditioning regimen, and GvHD prophy-
laxis, the addition of ATG to MUD allo-HSCT with PBSC did
not increase relapse rate. Our registry data did not include sufficient
data to define the disease risk index in all patients. We acknowledge
that the disease risk index would have allowed better comparability
between groups and with published data. 
Cumulative incidence (CI) of TRM for all three groups appears to
not reach a plateau, most evident for the PBSC group ( Figure 2 A).
This may be explained by the observation that the majority ofClinical Lymphoma, Myeloma and Leukemia 2021 5 
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Figure 2 (A) Cumulative incidence of Transplant-related mortality (TRM), (B) probability of GRFS, and (C) cumulative incidence 

































6 Clipatients in the PBSC group developed extensive cGvHD, making
them more prone to infections and death. 
GRFS is an increasingly recognized outcome measure after allo-
HSCT. 39 GRFS is defined as lack of severe aGvHD grade III-IV,
cGvHD that necessitates systemic treatment, relapse, and death. 39-41
Our findings demonstrate that ATG increases GRFS by reducing
severe acute and chronic GvHD which most likely increases quality
of life (QoL). Severe aGVHD and cGVHD have a detrimental
impact on QoL and patient suffering. 42 
EBV reactivation and EBV-related post-transplant lymphoprolif-
erative disease (PTLD) have been shown to be associated with T-
cell depletion using ATG formulations 43,44 and pretransplant EBV
sero-status. As expected, the occurrence of EBV reactivation was
significantly higher in the PBSC + ATG group compared to the
BMSC and PBSC groups. We now perform weekly monitoring
with quantitative EBV-PCR in blood until 4 months after allo-
HSCT for all patients who receive ATG. After the implementation
of weekly monitoring and preemptive treatment with rituximab, wenical Lymphoma, Myeloma and Leukemia 2021 
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PBSC + ATG group. 
Supportive care before, during, and after HSCT has improved
in recent years 45 and could have had an impact on the study, but
in the multivariate analysis we included “year of HSCT” to correct
for treatment changes performed during this time frame. The retro-
spective nature of our data is a limitation. Our study population is
heterogeneous in terms of disease type, disease stage, and condition-
ing regimen. Comparing our study with data from available clinical
trials using ATG as part of the GvHD prophylaxis is challenging due
to differences among studies in terms of ATG dosing, timing, length
of administration, type of preparation, and transplant characteristics
including disease group, donor type, graft source, and condition-
ing regimen. 23,27,28 Nonetheless, our data support previous reports
that a dramatic reduction in cGvHD may be accomplished by
ATG. 
Our study shows that the addition of low-dose (4 mg/kg) ATG in
allo-HSCT decreases the incidence of GvHD and notably increaseslin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells 
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Table 3 Multivariate Analysis for Various Outcome 
Variables Corrected for Differences Between the 
Groups. Corrected for (Patient and Donor Age, 
Diagnosis, Disease Stage, RIC/MAC and GvHD 
Prophylaxis), and Year of HSCT 
HR, 95% CI, p-value 
Mortality 
BMSC 0.96, 0.37-2.48, 0.93 
PBSC 0.90, 0.38-2.13, 0.80 
PBSC + ATG Ref 
TRM 
BMSC 0.96, 0.37-2.48, 0.92 
PBSC 0.90, 0.38-2.13, 0.80 
PBSC + ATG Ref 
Relapse 
BMSC 2.11, 0.81-5.49, 0.13 
PBSC 1.13, 0.44-2.93, 0.80 
PBSC + ATG Ref 
Acute GVHD II-IV 
BMSC 1.65, 0.81-3.35, 0.17 
PBSC 1.81, 0.92-3.57, 0.08 
PBSC + ATG Ref 
Acute GVHD III-IV 
BMSC 1.81, 0.47-6.95, 0.39 
PBSC 1.84, 0.51-6.66, 0.35 
PBSC + ATG Ref 
Chronic GVHD 
BMSC 1.87, 0.90-3.87, 0.09 
PBSC 5.49, 2.82-10.7, < 0.001 
PBSC + ATG Ref 
GRFS 
BMSC 2.00, 1.05-3.79, 0.03 
PBSC 1.67, 0.92-3.05, 0.09 
PBSC + ATG Ref 





























































GRFS, thus illustrating the benefit of ATG in addition to standard
GvHD prophylaxis in allo-HSCT. 
Clinical Practice Points 
 Allogeneic stem cell transplantation (allo-HSCT) is associated
with severe morbidity and mortality. Graft-versus-host disease
(GvHD) and relapse are major obstacles for cure and maintain-
ing good quality of life after transplantation. 
 Anti-thymocyte globulin (ATG) is commonly used to prevent
GvHD after allo-HSCT. In 2014 we added ATG to the GvHD
prophylaxis regimen for patients undergoing allo-HSCT with
peripheral stem cells (PBSC) from matched unrelated donor
(MUD) at our institution. We administered a low dose ATG
(Thymoglobulin) of 2 mg/kg/day in 2 days (total dose 4 mg/kg)
for PBSC 10/10 MUD. 
Please cite this article as: M.M. Ali et al, Addition of Anti-thymocyte Globu
From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Re
//doi org/10 1016/j clml 2021 05 003 We compare the outcome of 415 adult patients with haematolog-
ical malignancies undergoing allo-HSCT with MUD and PBSC
with or without ATG. 
 There was no significant difference in disease stage at transplanta-
tion, gender mismatch, stem cell dose, or CMV serological status
pretransplant between the patients who received and those who
did not receive ATG. Patients who received ATG were signifi-
cantly older, received grafts from younger donors, and had the
highest proportion of myelodysplastic syndrome, and a signif-
icantly higher number received reduced intensity conditioning
(RIC) regimen. 
 The incidence of chronic GvHD was dramatically reduced in
patients receiving MUD PBSC with low-dose ATG in the GvHD
prophylaxis regimen without increasing the incidence of relapse
or leading to more graft failure. 
 Our data support previous reports that the addition of ATG to
the standard GvHD prophylaxis decreases the incidence of both
acute and chronic GvHD and increases the GvHD-free, relapse-
free survival significantly. 
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